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Clinical conﬁnementTobacco toxicant-related exposure reduction is an important tool in harm reduction. Cigarette per day
reduction (CPDR) occurs as smokers migrate from smoking cigarettes to using alternative tobacco/nico-
tine products, or quit smoking. Few reports characterize the dose–response relationships between CPDR
and effects on exposure biomarkers, especially at the low end of CPD exposure (e.g., 5 CPD). We present
data on CPDR by characterizing magnitudes of biomarker reductions. We present data from a well-
controlled, one-week clinical conﬁnement study in healthy smokers who were switched from smoking
19–25 CPD to smoking 20, 10, 5 or 0 CPD. Biomarkers were measured in blood, plasma, urine, and breath,
and included smoke-related toxicants, urine mutagenicity, smoked cigarette ﬁlter analyses (mouth level
exposure), and vital signs. Many of the biomarkers (e.g., plasma nicotine) showed strong CPDR dose–
response reductions, while others (e.g., plasma thiocyanate) showed weaker dose–response reductions.
Factors that lead to lower biomarker reductions include non-CPD related contributors to the measured
response (e.g., other exposure sources from environment, life style, occupation; inter-individual variabil-
ity). This study conﬁrms CPDR dose-responsive biomarkers and suggests that a one-week design is
appropriate for characterizing exposure reductions when smokers switch from cigarettes to new tobacco
products.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
There are known epidemiological links between cigarette smok-
ing and several major diseases (U.S. Department of Health and
Human Services, 2010). Individual smokers can reduce their risk
for disease by quitting (IARC, 2007; U.S. Department of Health
and Human Services, 1990), and they may also be able to reduce
risk, albeit to a much lesser extent (Hatsukami et al., 2006b), by
reducing their cigarette per day (CPD) consumption (Lee, 2013).
Other options include switching to lower risk products as part of
a harm reduction approach (Fagerström and Bridgman, 2014;
McNeill and Munafo, 2013). Long-term cessation/abstinence is
generally accepted as being the most effective intervention (U.S.
Department of Health and Human Services, 2010).There is a considerable body of literature on how best to achieve
harm reduction for smokers, with major reviews on the subject
published in 2001 (Institute of Medicine, 2001) and in 2011
(Institute of Medicine, 2011). Discussions of biomarkers are ubiq-
uitous in these reviews. Use of the generic term ‘‘biomarker’’ is
used here and deﬁned as ‘‘a characteristic that is objectively mea-
sured and evaluated as an indicator of normal biological responses,
pathogenic processes, or pharmacologic responses to an intervention’’
(Institute of Medicine, 2011).
The Family Smoking Prevention and Tobacco Control Act was
implemented in 2009. Since then, tobacco products are regulated
by the Food and Drug Administration, Center for Tobacco Products
(FDACTP) in theUS (U.S. Congress, 2009). In this context, biomarkers
are considered to be an integral part of the requirements of an effec-
tive risk evaluation andmitigation strategy. For example, regulatory
submissions to the FDA CTP (e.g., via the Premarket Review of New
Tobacco Products Application, Modiﬁed Risk Tobacco Products
Application or Substantial Equivalence Application) could include
clinical studies involving biomarkers as part of a larger test strategy.
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2009) is also the establishment of a list of known toxicants of inter-
est, ‘‘Harmful and Potentially Harmful Constituents’’ (HPHC) that
are considered to be present in tobacco or in tobacco smoke
(Rodgman, 2011; U.S. Department of Health and Human Services,
2011). Presumably, these components are collectively those known
to be most likely responsible for the increased risk of disease in
smokers. However, there are few reports of direct, one-to-one rela-
tionships between a smoke component and a disease (Hatsukami
et al., 2006a; U.S. Department of Health and Human Services,
2010). Attempts have been made to link individual HPHC in smoke
with individual biomarkers (Shepperd et al., 2013a; Shields, 2002),
with one author suggesting that ‘‘no single biomarker will likely sat-
isfy our assessment needs, and so a panel of biomarkers should be used
that includes biomarkers of exposure, biologically effective dose, and
potential harm’’ (Shields, 2002). An abbreviated list of 18 HPHC in
cigarette smoke (acetaldehyde, acrolein, acrylonitrile, 4-aminobi-
phenyl, 1-aminonaphthalene, 2-aminonaphthalene, ammonia,
benzene, benzo[a]pyrene, 1,3-butadiene, carbon monoxide, croton-
aldehyde, formaldehyde, isoprene, nicotine (total), NNK, NNN, and
toluene) has been published (U.S. Department of Health and
Human Services, 2012).
When users of the most toxic tobacco products, cigarettes,
switch to other, less toxic products (e.g., smokeless tobacco), pro-
nounced reductions in concentrations of biomarker have been
reported (Sarkar et al., 2010). However, cigarette smokers often
do not make a complete switch, but instead use more than a single
type of tobacco product, termed ‘‘polytobacco use’’ (Bombard et al.,
2009), or simply ‘‘dual use’’ (Frost-Pineda et al., 2010; Klesges et al.,
2011; Lee, 2014; Lund and McNeill, 2013). Smokers may also con-
comitantly use nicotine replacement therapy, NRT (Beard et al.,
2013) or e-cigarettes (Farsalinos et al., 2014).
Different tobacco products and different scientiﬁc questions
will certainly need different biomarkers to assess their effects:
for example, smokeless tobacco products and e-cigarettes do
not produce carbon monoxide (CO) so that measurement of bio-
markers of CO uptake (e.g., blood or breath carboxyhemoglobin,
COHb) would be of no value, except, perhaps, for initially demon-
strating that levels of CO and COHb simply do not change as a
result of exposure to non-combustible products (Van Staden
et al., 2013).
There are reports in the literature of the effects of cessation on
biomarkers (Carmella et al., 2009). Much less common are reports
of effects on biomarkers following switching to lower yield prod-
ucts (Hecht et al., 2005), or to reduced risk products (Sarkar
et al., 2008; Shepperd et al., 2013b; Shields, 2002). This is espe-
cially the case where the ‘‘switching’’ is in fact ‘‘reduction’’ to smal-
ler numbers of CPD (Benowitz et al., 1986; Joseph et al., 2005).
Critically, there do not appear to be any published reports on likely
biomarker patterns in different types of dual use. It is probable that
in most cases of dual use the number of CPD will be less than the
CPD under the cigarettes-only condition (Benowitz et al., 1998;
Lund and McNeill, 2013; Scherer and Lee, 2014), following the
‘‘nicotine titration’’ hypothesis (McMorrow and Foxx, 1983). Under
such circumstances, the contribution of combusted tobacco prod-
uct to effects, as measured by individual biomarkers, should be
clearly understood.
Studies reported in the literature that characterize dual use
effects have key limitations that this study was designed to
directly overcome. First, most reported studies typically target
only a single CPDR level (probably because of the complexities
of conducting a study with multiple CPD exposure levels). The
present study includes multiple CPDR levels, adding value by pro-
viding a dose–response understanding and separating only the
contribution of cigarette smoking exposure to any potential dual
use scenario (or quitting via CPDR). Second, because this studysystematically veriﬁed CPD exposure during the screening and
in-clinic phases, this study has the key advantage of eliminating
a fundamental confounder present in previous studies: unreliable
self-reports of cigarette consumption (Caraballo et al., 2001).
Third, unlike other studies, the design of this study also
controlled diet, eliminating another known confounder for some
biomarkers (Scherer, 2006). Fourth, this study addressed the
literature data gaps related to characterization of CPDR effects
in the low range of CPD exposure, as there are practically no
well-controlled studies characterizing the effects of low range
CPDR (e.g., 65 CPD). Understanding the effects of low CPD
exposure is important as more smokers choose to migrate to
smokeless products, or to e-cigarettes, or to quit smoking
completely using a CPDR approach.
The primary objective of this study was to characterize the
effects of CPDR on different biomarkers of tobacco exposure (e.g.,
magnitudes of changes) in generally healthy, veriﬁed, adult smok-
ers without use of other tobacco/nicotine-containing products
(e.g., smokeless tobacco products, e-cigarettes, nicotine replace-
ment therapies). The secondary objectives of this study were to
characterize the effects of CPDR on ‘‘mouth level exposure’’ (MLE,
also known as ‘‘yield in use’’) (St. Charles et al., 2009) and subjec-
tive responses (questionnaires).
The hypothesis of this study was that, by separating the contri-
bution of CPD exposure-related effects to any potential dual/poly-
tobacco use scenario, the results would provide comparative
information on the value of different biomarkers, when used in dif-
ferent scenarios of polytobacco use. Such exposure scenarios
would include concomitant smoking and NRT use, or concomitant
smoking and low-exposure tobacco products use (e.g., smokeless
tobacco, e-cigarettes) that are anticipated to approximate to cessa-
tion in terms of their effect on different combustion-related toxi-
cants/biomarkers (but probably not on their effect on biomarkers
relating to nicotine exposures, if the alternate products contain
nicotine). This is important because there is also the possibility
of using biomarkers as proxies for characterizing the risk of
tobacco-related disease (Boffetta et al., 2006; Camacho et al.,
2014; Hatsukami et al., 2009; Institute of Medicine, 2001, 2011;
Shields, 2002).2. Materials and methods
2.1. Institutional review board approval
Prior to study commencement, the study protocol and the
informed consent form (ICF) were approved by a duly constituted
Institutional Review Board (IRB). The IRB for this study was Integ-
Review Ethical Review Board, 3001 South Lamar Boulevard, Suite
210, Austin, TX 78704.
This study was conducted in accordance with the applicable
principles of the United States (US) Code of Federal Regulations
(CFR) governing the protection of human subjects (21 CFR 50),
ﬁnancial disclosure by clinical investigators (21 CFR 54), and IRBs
(21 CFR 56). These regulations and the applicable International
Conference on Harmonization (ICH) guidelines are known as Good
Clinical Practice (GCP) and are consistent with the Declaration of
Helsinki.
The ICF included all elements required by ICH, GCP, and the US
Food and Drug Administration (FDA) as well as applicable local
regulatory requirements and adhered to the ethical principles that
have their origin in the Declaration of Helsinki.
Prior to undergoing any study procedures, subjects were fully
informed about the nature, scope, and possible consequences of
the study, and were asked to read, sign, and date the ICF. Each sub-
ject received a copy of the signed ICF.
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Subjects were clinic-conﬁned for 7½ days and were allowed
access to controlled target numbers of CPD (0, 5, 10, 20 CPD).
The study endpoints included a broad array of biomarkers mea-
sured in blood, plasma, 24-h urine, exhaled breath, smoked ﬁl-
ters/MLE (Morin et al., 2011; Nelson et al., 2011; Polzin et al.,
2009; Shepperd et al., 2011; St. Charles et al., 2009) and two sub-
jective questionnaires to monitor smoking urges or withdrawal
symptoms (Cox et al., 2001; Hughes and Hatsukami, 1986;
Tiffany and Drobes, 1991). The study also evaluated vital signs,
including heart rate, repeatedly demonstrated to be increased in
subjects who use some form of nicotine (Benowitz et al., 2002).
Unlike some short-term switching studies, after subjects were
acclimated for 2 days in-clinic (smoking up to 20 CPD), subjects
were then randomized and kept on their allocated target pattern
of cigarette usage (0, 5, 10 or 20 CPD) for 5½ days. This was done
to maximize stabilization of the biomarkers in subjects who chan-
ged substantially their daily consumption from the baseline.
This was a single-center, randomized, controlled, open-label,
parallel group study, designed to evaluate the effects of reduced
cigarette consumption on biomarkers of tobacco exposure in cur-
rent, healthy, veriﬁed, adult smokers. For intervention, subjects
were stratiﬁed by gender and randomized in parallel to one of 4
groups:
 ‘‘Maintainers’’ at 20 CPD (normalized from 19–25 CPD to 20 CPD
maximum),
 ‘‘Reducers’’ at 10 CPD (reduced from 19–25 CPD to 10 CPD
maximum),
 ‘‘Reducers’’ at 5 CPD (reduced from 19–25 CPD to 5 CPD maxi-
mum), and
 ‘‘Abstainers’’ at 0 CPD (reduced from 19–25 CPD to 0 CPD).
The sample size (minimum 30 per study group) was determined
based on total urinary nicotine equivalents. Previous data from 29
subjects on 4 different days were used to estimate the within- and
between-subject variability. The sample size recommended for this
study was considered adequate to detect a 25% reduction in total
nicotine equivalents between the 20 and 10 CPD groups with
80% power (5% signiﬁcance level; two-sided testing). To ensure
the balance of groups, randomization was stratiﬁed by gender.
The study was performed at the Orlando Clinical Research Cen-
ter (OCRC), 5055 South Orange Avenue, Orlando, FL 32809. The
study duration for individual subject participation was approxi-
mately 7½ weeks and included screening (Visits 1 and 2) up to
45 days prior to clinic check-in and a 7½ days clinic conﬁnement
period (Visit 3; Day-2 through Day 6). Subjects were discharged
on Day 6 following the completion of study procedures. Subjects
were enrolled in 6 consecutive cohorts over 6 sequential time peri-
ods until the total minimum required number of subjects was
reached.
Following completion of screening assessments, eligible sub-
jects returned to the clinic for conﬁrmation of continued eligibility
and admission to the clinical research unit on Day-2. The Fag-
erström Test for Nicotine Dependence (Fagerström, 1978) was
administered on Day-2 to estimate each subject’s degree of nico-
tine dependence. During the ﬁrst 2 days (acclimation period) of
clinic conﬁnement (Days-2 and -1), all subjects were provided with
an allotment of up to 20 CPD. On Day-1, subjects were randomly
assigned to 1 of the 4 CPD intervention groups, but were not
informed of group assignment until Day 1 (intervention period
start day). Subjects received cigarette allotments for each day
according to their group assignment.
Whole blood, plasma, serum, and 24-h urine samples for assess-
ment of biomarkers were collected before (Day-2 or -1) and after(Day 5 or 6) intervention. Breath samples for assessment of
exhaled carbon monoxide were collected daily from Day-2 to
Day 6.
Behavioral effects (based on subjective measures) of smoking
urges and nicotine withdrawal were assessed by administration
of the Brief Questionnaire of Smoking Urges (B-QSU) and Minne-
sota Nicotine Withdrawal (MNWS-R), questionnaires, respectively,
before (Day-1) and after (Day 5) intervention. Cigarette usage pat-
terns were assessed by daily CPD counts and the MLE assessments
of smoked cigarette butt length, ﬁlter tip nicotine, ﬁlter tip tar,
daily MLE tar, and daily MLE nicotine before (Day-1) and after
(Day 5) intervention.
Safety was evaluated based on data collected for adverse events
(AEs), physical examinations, vital signs, electrocardiograms
(ECGs), and clinical laboratory tests.
2.3. Subjects, inclusion–exclusion criteria, study products, and
randomization
Up to 160 subjects were planned for randomization to have at
least 120 subjects complete the study. A total of 123 subjects were
enrolled and 122 completed (one discontinued for family-related
reasons). All 123 enrolled subjects were included in the statistical
analyses. Healthy male and female adult smokers, 21–65 years of
age, currently conﬁrmed to smoke 19–25 CPD for at least the past
3 years were included.
Subjects who smoked cigarettes with no ﬁlters or charcoal ﬁl-
ters or used any non-tobacco burning cigarettes, including
tobacco-heating cigarettes or e-cigarettes, were excluded. Use of
any tobacco-based products (e.g., smokeless tobacco) other than
cigarettes or nicotine-replacement therapy within 3 months pre-
ceding clinic conﬁnement and use of cigars within 2 months of
clinic conﬁnement were also exclusionary. Subjects provided their
own usual brands (UB) of commercial, ﬁltered, tobacco-burning
cigarettes for use during the study and smoked up to the maximum
allotted CPD.
2.4. Biomarkers
Table 1 summarizes the smoke toxicant precursors for the bio-
markers measured in this study, the associated key toxicities trig-
gering interest in these biomarkers, the corresponding biomarkers
measured in this study (in blood, plasma, urine, and exhaled
breath), the laboratories where work was conducted, and the cor-
responding methods applied to measure the biomarkers.
Biological samples for primary biomarkers of exposure were
collected by OCRC staff during the in-clinic period (Visit 3) before
(Day-1) and after (Day 5) intervention (CPDR) and were analyzed
at the laboratories indicated in Table 1. Many of the selected bio-
markers were similar to those reported elsewhere (Gregg et al.,
2013; Institute of Medicine, 2011; Krautter and Borgerding,
2014). Analytical methods are essentially as recently reported else-
where (Krautter and Borgerding, 2014).
Urine extracts (from 24-h collections) were assayed for muta-
tion in the histidine-requiring Salmonella typhimurium strain
YG1024 (Sarkar et al., 2010), a descendant of TA98 (Aufderheide
and Gressmann, 2008), in the presence of a metabolizing system
(S-9, Molecular Toxicology, Boone, NC 28607) using a micro sus-
pension/pre-incubation modiﬁed assay (Kado et al., 1983).
Exhaled breath biomarkers (ECO and derived COHb) were mea-
sured daily (Days-2 through 6) by OCRC staff using a Smokerlyzer
breath carbon monoxide monitor (Bedford Scientiﬁc, Haddonﬁeld,
NJ).
Smoked cigarette ﬁlters were collected by OCRC staff before
(Day-1) and after (Day 5) intervention (secondary objective). MLE
data were reported per cigarette and were combined with the
Table 1
Biomarkers, precursors, biological samples, laboratories, and methods.
Precursor in tobacco/
smoke
Toxicitya Biomarker measured Primary
samples
Laboratory conducting
measurement
Method
Primary biomarkers of exposure
Carbon monoxide RDT Exhaled carbon monoxide (ECO)b Breath OCRC (USA) Smokerlyzer
Nicotine RDT, AD Nicotine equivalents Urineb ABF (Germany) LC–MS/MS
NNK, NNN, NAB, NAT NNK and
NNN: CA
Nitrosamines and metabolites
(NNAL + NNN + NAB + NAT + glucuronides)
LC–MS/MS
3-,4-Aminobiphenyl 4-ABP:
CA
3-,4-Aminobiphenyl (3-Abp, 4-Abp) GC/MS
2-Aminonaphthalene CA 2-Aminonaphthalene (2-ANaP) GC/MS
O-Toluidine CA O-Toluidine (O-Tol) GC/MS
Pyrene – 1-OH-pyrene (1-OH-Pyr) GC–MS/MS
Naphthalene CA, RT 1-,2-OH-naphthalene (1-OH-Nap, 2-OH-Nap) GC–MS/MS
Fluorene – 2-OH-ﬂuorene (2-OH-Flu) GC–MS/MS
Phenanthrene – 1-,2-,3-,4-,9-OH-phenanthrene (1-OH-Phe, 2-OH-Phe, 3-OH-
Phe, 4-OH-Phe, 9-OH-Phe)
GC–MS/MS
Acrylamide CA N-Acetyl-S-(2-carbamoylethyl)-L-cysteine (AAMA)/N-(R/S)-
acetyl-S-(2-carbamoyl-2-hydroxyethyl)-L-cysteine (GAMA)
LC–MS/MS
Acrolein RT, CT 3-Hydroxypropylmercapturic acid (HPMA) LC–MS/MS
Acrylonitrile CA, RT 2-Cyanoethylmercapturic acid (CEMA) LC–MS/MS
Ethylene oxide CA, RT,
RDT
2-Hydroxyethylmercapturic acid (HEMA) LC–MS/MS
Crotonaldehyde CA 3-Hydroxy-1-methylpropylmercapturic acid (HMPMA) LC–MS/MS
N/A – Creatinine Photometry
Benzo[a]pyrene CA 3-OH-benzo[a]pyrene (3-OH-B[a]p) Urinec Celerion (USA) SPE with LC–MS/MS
detection
1,3-Butadiene CA, RT,
RDT
Monohydroxy-3-butenyl-mercapturic acid (MHBMA) SPE with LC–MS/MS
detection
Benzene CA, CT,
RDT
S-phenyl mercapturic acid (S-PMA) SPE with LC–MS/MS
detection
N/A CA Urine mutagenicity Urinec Covance (UK) Salmonella assay
Nicotine RDT, AD Plasma nicotine (Nic), cotinine (Cot) Plasma Celerion (USA) Liquid–liquid extraction
with LC-MS/MS detection
Hydrogen cyanide RT, CT Thiocyanate (SCN) Plasma ABF (Germany) GC–MS
Carbon monoxide RDT Carboxyhemoglobin (COHb) Fresh
whole
blood
LabCorp Clinical Trials,
Burlington, NC (USA)
Absorption measurement
using IL-682 Co-oximeter
a Harmful and potentially harmful constituent (HPHC) classiﬁcations: carcinogen (CA), respiratory toxicant (RT), cardiovascular toxicant (CT), reproductive or develop-
mental toxicant (RDT), addictive (AD).
b ECO was measured using the Micro + Smokerlyzer.
c Urine biomarker analyses were assayed using aliquots from the 24-h urine collections. SPE, solid phase extraction; LC, liquid chromatography; MS, mass spectrometry;
GC, gas chromatography.
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Vital signs were measured daily in the clinic (Day-2 through
Day 6) by OCRC staff. Vital signs included heart rate, blood pres-
sure, body temperature (oral), and respiratory rate.2.5. Questionnaires
The following questionnaires were administered before (Day-1)
and after (Day 5) intervention by OCRC personnel: B-QSU and
MNWS-R. B-QSU Total Score represents the total urge to smoke.
Increases in B-QSU scores indicate greater urges to smoke, whereas
decreases in scores indicate a reduction in urges to smoke. The
MNWS-R includes both a self-assessment (15-items) completed
by subjects and an observer assessment (5-items) completed by
OCRC personnel. Increases in MNWS-R scores indicate increased
severity of nicotine withdrawal, whereas decreases in scores indi-
cate decreased severity of nicotine withdrawal.2.6. Statistical analyses
Several analyses were performed using SAS (Cary, NC) version
9.2. Among them, comparisons within each of the 4 CPD groups
comparing ‘‘after intervention’’ to ‘‘before intervention’’ were made
using paired t-tests.To evaluate the dose–response effects of reduced CPD consump-
tion on biomarkers, linear regression analyses were conducted for
% biomarker reduction vs. % CPDR. The regression analyses were
conducted on an individual subject basis and on a group mean
basis.
3. Results
3.1. Adverse events
Seven AEs occurred after subject randomization: 20 CPD: upper
respiratory tract infection in 1 subject (3%); 5 CPD: tooth infection
in 1 subject (3%); 0 CPD: syncope and heat stroke in 1 subject (3%
for each event), toothache in 1 subject (3%), skeletal injury in 1
subject (3%), contact dermatitis in 1 subject (3%), and rash in 1 sub-
ject (3%). All AEs were mild except for syncope, which was consid-
ered severe but did not require any intervention or therapy
(occurred during a blood draw and lasted for 1 min). No AEs were
related to UB cigarettes, intervention, or concomitant medications
monitored during the study.
3.2. Subjects and randomization
A tabular summary of demographic information is presented for
all randomized subjects as Table 2. The CPD groups were relatively
well-matched with respect to:
Fig. 1. Cigarettes consumed per day, before and after intervention. Means ± SD,
n = 30–31.
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 Age (mean 38.4–44.0 years).
 Race (75–90%White, 13–28% Black or African American) (1 sub-
ject each in the 10 and 5 CPD groups reported more than 1 race
and therefore totals exceed 100%).
 Ethnicity (10–17% Hispanic or Latino, 83–90% not Hispanic or
Latino).
 Body Mass Index (mean 26.6–29.1 kg/m2).
The mean FTND scores are also included in Table 2. Mean (±SD)
total dependence scores were 5.9 ± 1.62, 5.4 ± 1.65, 5.7 ± 1.82, and
6.0 ± 1.54 in the 20, 10, 5, and 0 CPD groups, respectively, corre-
sponding to a medium to high level of nicotine dependence in each
of the groups.
3.3. Cigarettes per day
Fig. 1 shows the mean (±SE, n = 30–31) veriﬁed CPD during the
in-clinic phase of the study. On Day-1, consumptions were similar
in each of the groups, with each of the mean values being close to
20 CPD. Post-intervention, there was very close adherence to the
maximum target values of 20 and 10 CPD. Adherence to the targets
in the 5 and 0 CPD groups was complete (no variation).Table 2
Demographics and characteristics before intervention.
Parameter 20 CPDa
N = 30
15 CPD
N = 30
10 CPD
N = 32
0 CPD
N = 31
Gender
Female 12 (40%) 12 (40%) 13 (41%) 13 (42%)
Male 18 (60%) 18 (60%) 19 (59%) 18 (58%)
Age (years)
Mean ± SD 38.3 ± 11.5 44.0 ± 11.2 42.3 ± 11.4 42.8 ± 9.02
Median 39.0 45.5 44.5 43.0
Min, max 21, 59 22, 63 21, 59 21, 60
Ethnicity
Hispanic/Latino 5 (17%) 3 (10%) 5 (16%) 5 (16%)
Not H/L 25 (83%) 27 (90%) 27 (84%) 26 (84%)
Raceb
White 25 (83%) 27 (90%) 24 (75%) 24 (77%)
Black 5 (17%) 4 (13%) 9 (28%) 7 (23%)
American Indian 0 1 (3%) 0 0
Height (cm)
Mean ± SD 170 ± 8.11 172 ± 11.2 172 ± 9.12 173 ± 10.0
Median 170 173 172 175
Min, max 153, 186 151, 190 156, 187 154, 193
Weight (kg)
Mean ± SD 79.8 ± 17.8 80.9 ± 19.4 87.5 ± 19.7 84.1 ± 16.6
Median 79.3 82.8 86.4 81.0
Min, max 48.6, 110 49.2, 122 44.5, 126 46.4, 131
BMI (kg/m2)
Mean ± SD 27.4 ± 5.25 27.0 ± 4.57 26.6 ± 6.64 28.1 ± 5.14
Median 26.6 26.1 28.0 27.1
Min, max 19.1, 36.9 20.5, 37.0 16.1, 43.6 19.7, 46.1
Total dependence
score
Very low (0–2) 0 1 (3%) 1 (3%) 0
Low (3–4) 6 (20%) 7 (23%) 8 (25%) 6 (19%)
Medium (5) 7 (23%) 9 (30%) 6 (19%) 7 (23%)
High (6–7) 13 (43%) 10 (33%) 12 (38%) 14 (45%)
Very high (8–10) 4 (13%) 3 (10%) 5 (16%) 4 (13%)
Mean ± SD 5.9 ± 1.62 5.4 ± 1.65 5.7 ± 1.82 6.0 ± 1.54
Median 6.0 5.0 6.0 6.0
Min, max 3, 9 2, 9 2, 9 3, 9
a Cigarettes per day.
b Subjects may have recorded more than one race (potentially counted in more
than one category).3.4. Biomarkers
Table 3 shows the mean (±SD, n = 30–31) concentrations of each
biomarker in each of the four groups, before and after intervention.
Typically, concentrations were very similar in each of the groups
before intervention, with considerable variation after intervention.
The changes produced by the intervention were reductions from
the 20 CPD values in the 10, 5 and 0 CPD groups.
Table 4 shows the mean (±SD, n = 30–31) change (%) in concen-
trations of each biomarker in the 10, 5 and 0 CPD groups after
intervention, compared with the values in the same groups before
intervention. Typically, changes were reductions from the 20 CPD
value by approximately 25%, 50% and 90% in the 10, 5 and 0 CPD
groups, respectively.
3.5. Regression
Table 5 also shows the results of linear regressions of % bio-
marker reductions (after intervention) vs. % CPDR, for blood and
urine biomarkers only. Three examples of linear regressions are
presented in Fig. 2.
4. Discussion
This study characterizes the magnitude of CPDR-driven changes
in biomarkers that can be expected within 5½ days of tightly-con-
trolled, in-clinic intervention, and ranks the biomarker responsive-
ness within this study design. While a few pairwise comparisons
between groups were not statistically signiﬁcant, CPDR generally
led to statistically signiﬁcant, proportionate reductions in most
blood, plasma, and urine biomarkers of exposure.
While CPDR led to exposure biomarker reductions that
appeared proportionate with CPDR, the degree of proportionality
varied considerably. For example, the urinary nicotine equivalents
response showed a much greater slope than did the plasma thiocy-
anate response. This is consistent with known elimination rates
and reports of contributions to thiocyanate exposure from other
sources (e.g., dietary, environmental, occupational, or life-style
exposures). Data presented indicate that: (1) different biomarkers
reduced to different extents during this short CPDR intervention
period; (2) as expected, none of the biomarkers reduced to zero;
(3) some biomarkers reduced fairly close to zero while others did
not reduce as substantially; (4) some biomarkers are clearly more
dose-responsive to CPDR than others.
Regression analysis results (Table 5) suggest that using 24-h
urine nicotine equivalents is a useful indicator of nicotine expo-
sure. Similar % reductions occur when measuring plasma nicotine
Table 3
Mean biomarker concentrations (±SD, n = 30–31) for each of the four groups, before and after intervention.
Biomarker (units) Before intervention After intervention
20 CPDa 10 CPD 5 CPD 0 CPD 20 CPD 15 CPD 5 CPD 0 CPD
Blood/plasma
Nicotine (ng/ml) 11.8 ± 5.9 11.3 ± 5.1 10.9 ± 5.4 12.3 ± 5.6 12.4 ± 5.5 7.9 ± 4.2 3.8 ± 1.9 0.2 ± 0.2
Cotinine (ng/ml) 278 ± 118 291 ± 95.4 280 ± 88.1 301 ± 124 279 ± 109 180 ± 61.1 92.9 ± 34.6 4.9 ± 5.0
Thiocyanate (lmol/l) 122 ± 46.5 126 ± 50.3 121 ± 36.8 128 ± 51.3 117 ± 38.0 107 ± 37.6 95.1 ± 25.9 88.3 ± 31.2
Carboxyhemoglobin (%) 5.4 ± 2.3 5.3 ± 1.5 5.2 ± 1.4 5.2 ± 1.8 5.4 ± 1.7 3.4 ± 1.1 1.9 ± 0.7 0.7 ± 0.3
Urine (24-h)
Nicotine (mg) 1.9 ± 1.1 2.6 ± 1.8 2.4 ± 1.4 2.8 ± 1.6 2.1 ± 1.2 1.4 ± 0.8 0.7 ± 0.4 0.0 ± 0.0
Cotinine (mg) 3.3 ± 1.6 3.3 ± 1.4 3.2 ± 1.0 3.4 ± 1.6 3.0 ± 1.5 1.9 ± 0.8 1.1 ± 0.4 0.1 ± 0.1
3-Hydroxycotinine (mg) 7.4 ± 3.7 9.1 ± 3.3 8.0 ± 3.9 8.5 ± 3.4 6.4 ± 3.0 4.9 ± 2.1 2.3 ± 0.8 0.2 ± 0.1
Nicotine glucuronide (mg) 1.8 ± 1.2 1.7 ± 1.3 1.5 ± 1.1 1.8 ± 1.4 1.9 ± 1.2 1.2 ± 1.1 0.6 ± 0.4 0.0 ± 0.0
Cotinine glucuronide (mg) 6.8 ± 3.7 6.7 ± 4.0 6.3 ± 4.0 6.4 ± 3.7 6.9 ± 3.6 4.2 ± 2.5 2.3 ± 1.4 0.2 ± 0.2
3-Hydroxycotinine glucuronide (mg) 4.4 ± 2.3 4.7 ± 2.2 5.0 ± 2.6 4.9 ± 2.6 4.4 ± 2.0 2.8 ± 1.4 1.6 ± 0.6 0.2 ± 0.1
Cotinine-N-oxide (lg) 840 ± 454 945 ± 406 800 ± 311 877 ± 344 782 ± 376 520 ± 196 260 ± 101 18.8 ± 16.4
Nicotine-N-oxide (mg) 1.2 ± 0.8 1.1 ± 0.5 1.1 ± 0.5 1.1 ± 0.6 1.4 ± 0.9 0.8 ± 0.3 0.5 ± 0.2 0.0 ± 0.0
Norcotinine (lg) 364 ± 154 399 ± 160 361 ± 121 377 ± 147 329 ± 132 215 ± 75.4 109 ± 37.4 10.0 ± 6.0
Nornicotine (lg) 208 ± 135 216 ± 137 177 ± 108 229 ± 116 184 ± 147 119 ± 73.6 52.6 ± 23.6 4.5 ± 4.7
Nicotine equivalents (mg) 19.5 ± 7.3 21.7 ± 7.0 20.1 ± 6.4 21.5 ± 5.7 18.8 ± 7.2 12.6 ± 4.0 6.5 ± 2.0 0.5 ± 0.3
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (ng) 692 ± 382 757 ± 398 726 ± 422 731 ± 399 624 ± 323 549 ± 304 422 ± 258 311 ± 265
N-nitrosonornicotine (ng) 22.3 ± 14.9 21.0 ± 13.5 20.7 ± 13.5 24.6 ± 26.3 21.2 ± 12.1 16.0 ± 11.9 9.7 ± 5.3 4.0 ± 3.0
N-nitrosoanabasine (ng) 111 ± 65.5 105 ± 68.5 103 ± 72.1 102 ± 67.3 111 ± 62.0 67.2 ± 40.9 41.3 ± 26.1 8.0 ± 6.9
N-nitrosoanatabine (ng) 653 ± 478 620 ± 461 551 ± 399 560 ± 359 657 ± 453 410 ± 306 218 ± 145 4.9 ± 10.2
3-Aminobiphenyl (ng) 10.5 ± 4.5 10.7 ± 4.8 11.7 ± 5.3 12.4 ± 4.9 9.8 ± 3.9 7.0 ± 2.9 4.9 ± 2.5 1.4 ± 1.1
4-Aminobiphenyl (ng) 25.9 ± 10.5 28.1 ± 11.1 26.6 ± 11.7 27.8 ± 7.9 22.4 ± 7.8 16.6 ± 6.6 10.9 ± 4.4 5.5 ± 2.7
2-Aminonaphthalene (ng) 34.1 ± 14.2 37.0 ± 14.3 34.3 ± 13.3 36.4 ± 8.9 31.2 ± 12.2 21.6 ± 8.5 12.1 ± 4.4 3.6 ± 1.4
O-Toluidine (ng) 190 ± 59.9 212 ± 61.3 194 ± 53.7 210 ± 63.5 190 ± 65.0 167 ± 52.8 129 ± 63.9 96.6 ± 38.9
S-phenyl-mercapturic acid (lg) 1.2 ± 0.6 1.1 ± 0.5 1.1 ± 0.5 0.9 ± 0.4 1.0 ± 0.4 0.7 ± 0.3 0.6 ± 0.2 0.4 ± 0.2
1-Hydroxypyrene (mg) 276 ± 133 265 ± 129 264 ± 158 313 ± 137 251 ± 120 167 ± 78.6 127 ± 55.1 114 ± 53.4
3-Hydroxy-benzo[a]pyrene (pg) 233 ± 132 195 ± 92.7 184 ± 84 242 ± 138 204 ± 106 127 ± 59.8 89.6 ± 46.6 67.8 ± 36.7
1-Hydroxynaphthalene (lg) 11.2 ± 5.1 15.7 ± 21.7 10.6 ± 4.7 10.6 ± 3.9 10.9 ± 4.8 7.3 ± 3.6 4.4 ± 1.9 1.8 ± 1.8
2-Hydroxynaphthalene (lg) 16.6 ± 6.0 18.8 ± 6.1 16.7 ± 6.4 17.6 ± 5.0 14.8 ± 5.4 10.8 ± 3.6 6.3 ± 1.9 2.7 ± 1.4
2-Hydroxyﬂuorene (lg) 1.7 ± 0.7 1.9 ± 0.8 1.8 ± 0.7 2.0 ± 0.6 1.6 ± 0.7 1.3 ± 0.5 0.9 ± 0.4 0.6 ± 0.2
1-Hydroxyphenanthrene (ng) 224 ± 97.4 228 ± 88.6 211 ± 73.0 238 ± 99.8 203 ± 83.6 161 ± 60.7 122 ± 47.5 105 ± 58.2
2-Hydroxyphenanthrene (ng) 117 ± 65.6 118 ± 63.3 101 ± 37.9 143 ± 92.2 116 ± 65.6 83.3 ± 41.0 55.1 ± 23.0 57.2 ± 40.8
3-Hydroxyphenanthrene (ng) 216 ± 84.2 228 ± 106 208 ± 68.8 246 ± 84.2 204 ± 77.6 160 ± 56.4 108 ± 38.9 75.1 ± 42.8
4-Hydroxyphenanthrene (ng) 60.7 ± 31.8 62.1 ± 32.3 54.8 ± 22.2 63.9 ± 26.4 57.8 ± 29.5 45.2 ± 22.0 31.8 ± 13.3 23.0 ± 18.6
9-Hydroxyphenanthrene (ng) 286 ± 162 292 ± 164 244 ± 113 284 ± 126 267 ± 140 208 ± 123 130 ± 69.2 73.1 ± 89.3
N-acetyl-S-(2-carbamoyl-ethyl)-L-cysteine (lg) 259 ± 82.9 270 ± 87.1 281 ± 92.4 289 ± 83.9 254 ± 71.8 234 ± 117 177 ± 64.4 166 ± 78.3
N-(R/S)-acetyl-S-(2-carbamoyl-hydroxyethyl-L-cysteine
(lg)
42.2 ± 16.8 45.8 ± 17.3 39.1 ± 12.5 43.8 ± 18.2 44.2 ± 16.0 45.0 ± 25.8 31.4 ± 12.4 32.7 ± 13.0
3-Hydroxypropyl mercapturic acid (mg) 2.2 ± 0.8 2.5 ± 0.9 2.2 ± -0.7 2.4 ± 0.8 2.0 ± 0.7 1.4 ± 0.5 0.9 ± 0.2 0.5 ± 0.2
2-Cyanoethyl mercapturic acid (lg) 240 ± 103 282 ± 128 245 ± 91.0 263 ± 83.4 218 ± 79.4 168 ± 75.2 93.2 ± 33.5 38.3 ± 15.3
2-Hydroxyethyl mercapturic acid (lg) 12.9 ± 7.8 14.6 ± 7.0 11.2 ± 7.5 14.3 ± 9.6 8.3 ± 3.8 7.8 ± 3.9 4.4 ± 2.0 4.8 ± 2.2
3-Hydroxy-1-methylpropyl mercapturic acid (lg) 685 ± 269 760 ± 279 657 ± 279 715 ± 230 598 ± 266 406 ± 154 319 ± 151 213 ± 131
Monohydroxy-3-butenyl-mercapturic acid (lg) 6.5 ± 4.5 7.5 ± 3.2 6.2 ± 3.8 5.8 ± 4.1 6.3 ± 4.1 4.3 ± 2.3 2.2 ± 1.2 0.5 ± 0.2
Mutagenicity (revertants  1000) 33.0 ± 19.0 36.0 ± 23.6 29.8 ± 17.7 34.1 ± 14.6 23.0 ± 15.0 17.3 ± 9.9 9.2 ± 5.4 2.7 ± 1.7
Creatinine (g) 1.6 ± 0.6 1.5 ± 0.5 1.5 ± 0.5 1.5 ± 0.5 1.5 ± 0.5 1.4 ± 0.4 1.5 ± 0.6 1.5 ± 0.4
Exhaled breath
Exhaled carbon monoxide (ppm) 26.9 ± 11.7 22.3 ± 6.2 23.0 ± 6.6 22.9 ± 7.2 22.9 ± 8.7 16.7 ± 5.0 12.6 ± 4.0 2.0 ± 0.7
Derived carboxyhemoglobin (%) 5.0 ± 1.9 4.2 ± 1.0 4.3 ± 1.1 4.3 ± 1.2 4.3 ± 1.4 3.3 ± 0.8 2.7 ± 0.6 1.0 ± 0.1
Mouth level exposure
Butt length (mm) 37.8 ± 4.9 36.0 ± 4.2 37.9 ± 5.6 36.4 ± 4.8 37.6 ± 4.4 33.9 ± 5.3 32.8 ± 7.3 n.a.
Filter tar (mg/cigarette) 21.0 ± 7.5 22.8 ± 6.5 20.7 ± 7.6 23.9 ± 7.9 21.2 ± 6.3 25.6 ± 6.8 24.1 ± 8.4 n.a.
Filter nicotine (mg/cigarette) 1.60 ± 0.55 1.73 ± 0.46 1.64 ± 0.69 1.78 ± 0.53 1.61 ± 0.47 2.02 ± 0.52 1.93 ± 0.73 n.a.
Mouth level tar exposure (mg/d) 403 ± 162 435 ± 127 400 ± 156 458 ± 167 398 ± 130 253 ± 67.8 121 ± 42.0 n.a.
Mouth level nicotine exposure (mg/d) 30.8 ± 11.9 33.0 ± 9.05 31.7 ± 14.0 34.1 ± 11.4 30.3 ± 9.82 20.0 ± 5.21 9.66 ± 3.66 n.a.
Questionnaires
Brief questionnaire on smoking urges, total score 63.1 ± 21.6 66.6 ± 20.6 59.1 ± 20.6 61.7 ± 24.1 55.1 ± 26.4 60.6 ± 22.0 62.2 ± 23.8 47.3 ± 35.2
Brief questionnaire on smoking urges, score 1 76.8 ± 22.6 78.1 ± 20.9 70.1 ± 26.7 74.2 ± 25.2 70.9 ± 27.9 73.8 ± 23.2 76.9 ± 25.3 56.9 ± 38.5
Brief questionnaire on smoking urges, score 2 41.4 ± 26.3 48.0 ± 26.2 43.1 ± 26.3 43.8 ± 27.8 32.5 ± 30.0 39.1 ± 27.8 38.5 ± 28.0 32.3 ± 32.8
Minnesota nicotine withdrawal scale – revised, total
score
16.1 ± 11.2 15.9 ± 9.3 12.6 ± 8.7 13.8 ± 9.0 14.4 ± 11.8 13.4 ± 7.6 14.8 ± 11.9 14.1 ± 11.9
Minnesota nicotine withdrawal scale – revised, score 1 12.0 ± 8.3 13.0 ± 6.9 10.6 ± 7.0 11.4 ± 7.2 10.3 ± 8.6 11.2 ± 6.7 12.1 ± 9.5 11.9 ± 9.7
Minnesota nicotine withdrawal scale – revised, score 2 4.1 ± 3.8 2.9 ± 3.6 2.0 ± 2.6 2.4 ± 2.9 4.0 ± 4.4 2.2 ± 2.2 2.7 ± 3.3 2.2 ± 3.3
Minnesota nicotine withdrawal scale – revised, observer
score, total score
0.6 ± 1.7 0.2 ± 0.6 0.3 ± 1.2 0.4 ± 1.2 2.2 ± 4.6 1.1 ± 2.0 1.2 ± 2.1 1.3 ± 2.5
Vital signs
Heart rate (beats per minute) 87 ± 8 84 ± 10 83 ± 11 87 ± 12 85 ± 8 85 ± 10 76 ± 10 76 ± 11
Means ± standard deviations; n = 30–31.
n.a. = not applicable.
a Cigarettes per day.
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Table 4
Mean % changes (±SD, n = 30–31) in biomarkers in 10, 5 and 0 CPD groups before and after intervention.
Biomarker (units) Per cent change
10 CPDa 5 CPD 0 CPD
Blood/plasma
Nicotine (ng/ml) 24 ± 42*** 62 ± 20*** 98 ± 2***
Cotinine (ng/ml) 37 ± 17*** 66 ± 8*** 98 ± 2***
Thiocyanate (lmol/l) 10 ± 20 20 ± 10 29 ± 13
Carboxyhemoglobin (%) 32 ± 20*** 64 ± 13*** 84 ± 8***
Urine (24-h)
Nicotine (mg) 33 ± 41*** 63 ± 23*** 99 ± 1***
Cotinine (mg) 38 ± 21*** 66 ± 14*** 98 ± 2***
3-Hydroxycotinine (mg) 44 ± 19*** 67 ± 13*** 97 ± 2***
Nicotine glucuronide (mg) 27 ± 40*** 32 ± 129 98 ± 5***
Cotinine glucuronide (mg) 34 ± 25*** 52 ± 54*** 96 ± 4***
3-Hydroxycotinine glucuronide (mg) 38 ± 21*** 64 ± 14*** 94 ± 5***
Cotinine-N-oxide (lg) 41 ± 21*** 65 ± 12*** 98 ± 2***
Nicotine-N-oxide (mg) 21 ± 25*** 53 ± 22*** 98 ± 2***
Norcotinine (lg) 39 ± 37*** 67 ± 14*** 97 ± 2***
Nornicotine (lg) 36 ± 37*** 66 ± 15*** 98 ± 3***
Nicotine equivalents (mg) 39 ± 20*** 66 ± 10*** 98 ± 1***
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (ng) 26 ± 15*** 42 ± 17*** 60 ± 12***
N-nitrosonornicotine (ng) 19 ± 31*** 51 ± 23*** 77 ± 23***
N-nitrosoanabasine (ng) 33 ± 22*** 57 ± 15*** 90 ± 8***
N-nitrosoanatabine (ng) 32 ± 24*** 58 ± 16*** 99 ± 4***
3-Aminobiphenyl (ng) 31 ± 21*** 56 ± 17*** 88 ± 10***
4-Aminobiphenyl (ng) 40 ± 13*** 57 ± 14*** 80 ± 10***
2-Aminonaphthalene (ng) 39 ± 17*** 63 ± 12*** 90 ± 4***
O-Toluidine (ng) 17 ± 28*** 34 ± 25*** 53 ± 17***
S-phenyl-mercapturic acid (lg) 29 ± 28*** 45 ± 27*** 56 ± 18***
1-Hydroxypyrene (mg) 31 ± 27*** 46 ± 23*** 61 ± 17***
3-Hydroxy-benzo[a]pyrene (pg) 30 ± 24*** 41 ± 51*** 63 ± 25***
1-Hydroxynaphthalene (lg) 38 ± 24*** 55 ± 20*** 79 ± 34***
2-Hydroxynaphthalene (lg) 41 ± 14*** 60 ± 12*** 85 ± 7***
2-Hydroxyﬂuorene (lg) 32 ± 17*** 48 ± 17*** 70 ± 8***
1-Hydroxyphenanthrene (ng) 21 ± 52*** 39 ± 25*** 50 ± 46***
2-Hydroxyphenanthrene (ng) 24 ± 23*** 44 ± 20*** 57 ± 21***
3-Hydroxyphenanthrene (ng) +100 ± 747 46 ± 21*** 67 ± 21***
4-Hydroxyphenanthrene (ng) 19 ± 46* 39 ± 25*** 58 ± 55***
9-Hydroxyphenanthrene (ng) 21 ± 43* 44 ± 28*** 67 ± 66***
N-acetyl-S-(2-carbamoyl-ethyl)-L-cysteine (lg) 11 ± 41 32 ± 31*** 40 ± 25***
N-(R/S)-acetyl-S-(2-carbamoyl-hydroxyethyl-L-cysteine (lg) 0 ± 48 16 ± 35* 22 ± 27***
3-Hydroxypropyl mercapturic acid (mg) 43 ± 18*** 57 ± 16*** 78 ± 13***
2-Cyanoethyl mercapturic acid (lg) 39 ± 16*** 60 ± 13*** 85 ± 5***
2-Hydroxyethyl mercapturic acid (lg) 42 ± 27*** 52 ± 21*** 59 ± 22***
3-Hydroxy-1-methylpropyl mercapturic acid (lg) 45 ± 14*** 50 ± 22*** 69 ± 19***
Monohydroxy-3-butenyl-mercapturic acid (lg) 41 ± 19*** 59 ± 16*** 83 ± 18***
Mutagenicity (revertants  1000) 48 ± 21*** 63 ± 30*** 92 ± 6***
Creatinine (g) 4 ± 22 +1 ± 33 +4 ± 25
Exhaled breath
Exhaled carbon monoxide (ppm) 22 ± 26*** 44 ± 15*** 90 ± 5***
Derived carboxyhemoglobin (%) 19 ± 21 *** 37 ± 13*** 75 ± 8***
Mouth level exposure
Butt length (mm) 6 ± 8*** 13 ± 18*** n.a.
Filter tar (mg/cigarette) +16 ± 28*** +19 ± 25*** n.a.
Filter nicotine (mg/cigarette) +19 ± 23*** +22 ± 33*** n.a.
Mouth level tar exposure (mg/d) 40 ± 15*** 69 ± 7*** n.a.
Mouth level nicotine exposure (mg/d) 38 ± 12*** 68 ± 9*** n.a.
Questionnaires
Brief questionnaire on smoking urges, total score +5 ± 96 +40 ± 157 27 ± 47***
Brief questionnaire on smoking urges, score 1 +5 ± 72 +34 ± 109 24 ± 46***
Brief questionnaire on smoking urges, score 2 +9 ± 174 +73 ± 372 28 ± 48***
Minnesota nicotine withdrawal scale – revised, total score +13 ± 109 +67 ± 159* +16 ± 111
Minnesota nicotine withdrawal scale – revised, score 1 +10 ± 97 +56 ± 145* +14 ± 94
Minnesota nicotine withdrawal scale – revised, score 2 +29 ± 146 +67 ± 145* +9 ± 109
Minnesota nicotine withdrawal scale – revised, observer score, total score +83 ± 202* +91 ± 61*** +97 ± 258*
Vital signs
Heart rate (beats per minute) +2 ± 12 7 ± 10*** 12 ± 12***
Means ± standard deviations; n = 30–31.
n.a. = not applicable.
a Cigarettes per day.
* p < 0.05.
** p < 0.01.
*** p < 0.001.
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Table 5
Results of linear regressions of % CPDR and % reduction in biomarker concentrations, for individual data and group means.
Biomarker (units) Regressiona on individual values Regressiona on mean values
Slope Intercept R2 Slope Intercept R2
Blood/plasma
Nicotine (ng/ml) 1.17 27.8 0.29 1.04 14.1 0.96
Cotinine (ng/ml) 0.96 4.1 0.86 1.00 6.2 0.99
Thiocyanate (lmol/l) 0.27 0.4 0.29 0.29 1.6 0.98
Carboxyhemoglobin (%) 0.87 5.5 0.71 0.92 7.8 0.99
Urine (24-h)
Nicotine (mg) 1.15 21.8 0.49 1.23 26 1.00
Cotinine (mg) 0.88 2.4 0.75 0.91 0.87 0.98
3-Hydroxycotinine (mg) 0.85 6.4 0.75 0.87 5.1 0.99
Nicotine glucuronide (mg) 1.08 18.4 0.63 1.09 20 0.97
Cotinine glucuronide (mg) 0.99 8.9 0.79 1.01 10.1 0.99
3-Hydroxycotinine glucuronide (mg) 0.95 4.9 0.76 0.97 6.1 0.99
Cotinine-N-oxide (lg) 0.92 0.03 0.76 0.94 0.7 0.99
Nicotine-N-oxide (mg) 1.19 30.4 0.73 1.22 31 0.98
Norcotinine (lg) 0.86 4.9 0.66 0.88 2.9 0.98
Nornicotine (lg) 0.84 5.1 0.53 0.89 2.8 0.96
Nicotine equivalents (mg) 0.91 0.21 0.81 0.94 1.4 0.99
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (ng) 0.52 4.13 0.57 0.54 3.2 0.98
N-nitrosonornicotine (ng) 0.92 17.3 0.40 0.92 17.0 0.98
N-nitrosoanabasine (ng) 0.94 8.7 0.77 0.95 9.3 0.99
N-nitrosoanatabine (ng) 1.01 11.4 0.73 1.03 12.6 0.97
3-Aminobiphenyl (ng) 0.82 0.1 0.71 0.84 1.6 0.96
4-Aminobiphenyl (ng) 0.69 8.4 0.77 0.69 8.3 0.99
2-Aminonaphthalene (ng) 0.82 3.4 0.40 0.84 2.4 0.99
O-Toluidine (ng) 0.52 3.7 0.40 0.54 4.7 0.97
S-phenyl-mercapturic acid (lg) 0.50 5.8 0.33 0.51 5.3 1.00
1-Hydroxypyrene (mg) 0.56 4.7 0.45 0.56 4.6 1.00
3-Hydroxy-benzo[a]pyrene (pg) 0.55 3.8 0.26 0.57 2.6 0.98
1-Hydroxynaphthalene (lg) 0.77 0.4 0.54 0.79 1.5 1.00
2-Hydroxynaphthalene (lg) 0.72 8.7 0.79 0.74 7.7 0.99
2-Hydroxyﬂuorene (lg) 0.61 4.7 0.68 0.63 3.9 0.99
1-Hydroxyphenanthrene (ng) 0.43 5.3 0.15 0.44 4.5 0.97
2-Hydroxyphenanthrene (ng) 0.58 1.2 0.49 0.59 1.9 1.00
3-Hydroxyphenanthrene (ng) 0.62 1.2 0.50 0.63 0.3 0.98
4-Hydroxyphenanthrene (ng) 0.56 1.3 0.22 0.57 2.2 0.95
9-Hydroxyphenanthrene (ng) 0.61 0.4 0.22 0.63 1.4 0.95
N-acetyl-S-(2-carbamoyl-ethyl)-L-cysteine (lg) 0.45 4.9 0.22 0.45 4.7 0.96
N-(R/S)-acetyl-S-(2-carbamoyl-hydroxyethyl-L-cysteine (lg) 0.35 12.6 0.12 0.33 11.3 0.95
3-Hydroxypropyl mercapturic acid (mg) 0.69 7.1 0.66 0.71 6.1 1.00
2-Cyanoethyl mercapturic acid (lg) 0.77 4.0 0.78 0.79 2.9 0.99
2-Hydroxyethyl mercapturic acid (lg) 0.34 24.9 0.22 0.36 24.2 1.00
3-Hydroxy-1-methylpropyl mercapturic acid (lg) 0.55 13.2 0.51 0.56 13.0 0.97
Monohydroxy-3-butenyl-mercapturic acid (lg) 0.84 2.5 0.70 0.87 4.0 1.00
Mutagenicity (revertants  1000) 0.68 17.2 0.44 0.70 16.3 0.97
Creatinine (g) 0.09 5.5 0.02 0.09 5.8 0.84
a Regression data (linear) are for biomarker reductions (%) vs. CPDR (%).
Fig. 2. Relationships between individual % reductions in cigarettes per day and
individual % reductions in biomarker concentrations, for three different biomarkers.
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may act as an ‘‘integrator’’ of nicotine intake, with nicotine equiv-
alents in 24-h urine generally accepted to account for about 90% of
the daily nicotine exposure (Benowitz et al., 2009).Exhaled breath CO, much less invasive to obtain than blood
COHb, is a rapid and effective cigarette smoke exposure biomarker.
Such measurements would typically be of no value in studies
where products such as smokeless tobacco and e-cigarettes are
evaluated on their own without comparison to cigarette smoke,
since such products do not produce CO (Van Staden et al., 2013).
For biomarkers with long half-lives (e.g., plasma thiocyanate
and urine NNAL), the lower maximum % reductions (29% for thio-
cyanate and 60% for NNAL) with 0 CPD are not unexpected consid-
ering the 5½-day intervention period in this study. For example,
based on the reported half-lives of plasma thiocyanate (Junge,
1985) and urine total NNAL in smokers (Goniewicz et al., 2009),
maximum % reductions would occur at approximately 30 and
50 days, respectively. Thiocyanate has also been shown to be of
limited value as a biomarker for cigarette smoke exposure, because
of numerous sources of both thiocyanate and the precursor hydro-
gen cyanide in the diet (Scherer, 2006).
Reductions in urine mutagenicity occurred with 10, 5, and 0
CPD vs. 20 CPD, as reported in smokers who switched to snus
(Sarkar et al., 2010). The most substantial reductions in urine
mutagenicity occurred with 5 and 0 CPD vs. 20 CPD. The bland diet
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substantial decrease even in the 20 CPD group at the end of inter-
vention. Urine mutagenicity reductions in this study are consistent
with previously reported data (Doolittle et al., 1989). This ‘‘bio-
marker’’ is highly relevant because: (1) it reﬂects exposure to
potential mutagens, (2) it goes beyond measurement of individual
chemicals to capture an integrative toxicological response in an
integrative biological matrix (24-h urine), and (3) it follows a clear
dose–response with CPDR, even in this short time-frame.
The CPDR from 20 to 10, 5, and 0 led to daily MLE tar and nic-
otine yields that were statistically signiﬁcantly decreased in the 10
and 5 vs. 20 CPD, as expected. Daily MLE tar and nicotine were well
correlated with mean CPD. Data for the MLE set of biomarkers indi-
cate a slightly more intense smoking of cigarettes in the 10 and 5
CPD groups than in the 20 CPD group. This intensity is shown to
be increased through slightly shorter butt lengths and slightly
higher tar and nicotine concentrations in ﬁlters from smoked ciga-
rettes. This amount of ‘‘compensation’’ (Scherer, 1999) as a conse-
quence of the ‘‘nicotine titration’’ theory (McMorrow and Foxx,
1983) is however, quite low (a mean of 22% in smokers switched
from 20 to 5 CPD), compared with other reports (Benowitz,
2001) where it is suggested that compensation can be much
higher. Compensatory smoking has previously been shown
(Hatsukami et al., 2006b) to limit the harm reduction value of
decreased smoking of cigarettes, but the biological signiﬁcance of
the small changes reported here is questionable. An update on
the literature relating to compensatory smoking is available
(Scherer and Lee, 2014).
Reductions in CPD did not have major effects on vital signs
except for the fact that CPDR led to consistent reductions in heart
rate with 5 and 0 CPD, with a transient decrease in the 10 CPD
group. Based on these data, and consistent with other reports
(Swan et al., 2007), heart rate is a useful biomarker despite the
inherent high variability in the assay, because it is almost com-
pletely non-invasive and is well-known to be linked to nicotine
(Benowitz et al., 2002).
There was effectively no correlation between CPDR and data
obtained from questionnaires, indicating their irrelevance as a
CPDR assessment procedure.
A limitation of this work is that the intervention was of only
5½ days duration. Different ﬁndings may be expected were longer
interventions used, particularly for the 0 CPD group. Conversely,
there are major logistical problems associated with longer-term
isolation of large numbers of volunteer smokers. Another limita-
tion includes the fact that there could be non-CPD exposure-
related sources (environment, life style, occupation, etc.) that could
impact some biomarkers (i.e., CPDR effects may not be as pro-
nounced for some biomarkers because there is a signiﬁcant under-
lying contribution to some biomarkers from non CPD-related
sources). A further limitation is that there is inherent inter-individ-
ual variability that can impact biomarker responses.
In conclusion, the results of this study (1) demonstrate that the
extent of reduction observed varies for different exposure bio-
markers in response to controlled reductions in cigarettes smoked
per day and (2) establishes the degree of direct proportionality
between individual biomarker reductions and CPDR. Results of this
study point to the utility of an abbreviated, CPD dose-responsive,
non-invasive biomarker list, where the need justiﬁes. For example,
for conventional tobacco-burning cigarettes, some of the most
CPDR dose-responsive biomarkers are exhaled breath carbon mon-
oxide, 24-h urine nicotine equivalents, blood COHb, heart rate,
daily MLE, and urine mutagenicity. This study also suggests that
a one-week reduction/cessation design is an appropriate tool for
characterizing exposure reductions when smokers switch from
cigarettes to smokeless tobacco or to new tobacco products such
as e-cigarettes or dissolvable tobacco products.Conﬂict of interest
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